Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06109870 · ClinicalTrials.gov registry record · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
A NA study of Hpv, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 920
- Enrollment target
- 2
- Study locations
NCT06109870: Recruiting NA study of Hpv, sponsored by M.D. Anderson Cancer Center.
NCT06109870 is a NA study of Hpv that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 920 participants, below the 2,203-participant average among 24 other Hpv trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06109870, a NA study of Hpv, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 920 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.
Conditions Studied
Interventions
- BEHAVIORAL PRECEDE-PROCEED
Study Locations (2)
Texas
- University of Texas at Austin - Austin
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2030-08-31 |
| Phase | NA |
What NCT06109870 shows while recruiting
NCT06109870 is an interventional study that assigns participants to a tested intervention. The registered 920 participants enrollment target is mid-sized for trials with a published cap, below the 2,203-participant average among 24 other Hpv trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which PRECEDE-PROCEED is the first listed.
NCT06109870 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06109870 about?
NCT06109870 is a clinical study titled "Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening". Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.
What is the current status of trial NCT06109870?
This trial is currently recruiting. It is a NA study. The enrollment target is 920 participants. The study started on 2023-10-30. Estimated completion is 2030-08-31.
What conditions does trial NCT06109870 study?
This clinical trial studies the following conditions: Hpv.
What interventions are being tested in trial NCT06109870?
The interventions under investigation include: PRECEDE-PROCEED (BEHAVIORAL).
Who is sponsoring clinical trial NCT06109870?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06109870 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06109870's enrollment target sits among peer trials
920 6th of 24 higher than 19 of 24 other Hpv trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hpv trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
HPV Self-Collection Program
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
Playing Game to Learn About Children's Vaccine Project
RECRUITING · NA
-
Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
- NCT07174336 · 920 participants · Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- NCT07151001 · 922 participants
Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI